SpinalCyte to Provide Clinical Trial Update at the 2019 International Society for the Advancement of Spine Surgery Annual Meeting

HOUSTON–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/celltherapy?src=hash" target="_blank"gt;#celltherapylt;/agt;–SpinalCyte, LLC, a Texas-based regenerative medicine company focused on
regrowth of the spinal disc using Human Dermal Fibroblasts (HDFs), today
announced that Thomas Ichim, Ph.D., SpinalCyte’s Chief Scientific
Officer, will present at the 2019 International Society for the
Advancement of Spine Surgery Annual Meeting (ISASS19) on Thursday, April
4, 2019 at 7:50 a.m. PDT in Anaheim, CA.

The presentation entitled, “Double Blind Placebo Controlled Clinical
Trial of Universal Donor Fibroblast Product CybroCell™ for Treatment of
Disc Degenerative Disease,” will include updates from SpinalCyte’s Phase
I/II clinical trial for CybroCell™ including new 16-month data.
Previously presented 12-month pain and MRI data showed continued pain
relief and improved disc heights. Recent clearance by the FDA for
SpinalCyte’s Investigational New Drug protocol has paved the way for the
company’s continued clinical trials and commercialization of its
fibroblast cell therapy.

About Degenerative Disc Disease

Degenerative disc disease (DDD) is a condition in which a patient’s
spinal disc breaks down and can begin to collapse. It is estimated that
85% of people over the age of 50 have evidence of disc degeneration and
over 1.3 million procedures a year are performed to treat the disease.
The most common treatments for patients with DDD are either discectomy
or spinal fusion. Discectomy is the partial or full removal of the
degenerated disc to decompress and relieve the nervous system but can
cause long term pain. In a spinal fusion procedure, the entire disc is
removed and the two adjacent vertebrae are fused together. It often
increases strain on the adjacent discs and surrounding tissues leading
to further degeneration.

About CybroCell

CybroCell™ is the first off-the-shelf allogenic human dermal fibroblast
(HDF) product for the treatment of degenerative disc disease.
SpinalCyte’s Phase 1/Phase 2 clinical trial for injected human dermal
fibroblasts in the treatment of DDD demonstrated sustained improvement
in pain relief and mobility beyond the 12-month endpoint.

About SpinalCyte

Based in Houston, Texas, SpinalCyte, LLC, is a regenerative medicine
company developing an innovative solution for spinal disc regeneration
using human dermal fibroblasts. Currently, SpinalCyte holds 39 U.S. and
international issued patents and has filed for an additional 100+
patents across a variety of disease pathways, including disc
degeneration, cancer, diabetes, liver failure and heart failure. Funded
entirely by angel investors, SpinalCyte represents the next generation
of medical advancement in cell therapy. Visit www.spinalcyte.com.

Contacts

David Schull
[email protected]
Ned
Berkowitz
[email protected]
Russo
Partners LLC
858-717-2310
646-942-5629

Clinical Contact:
[email protected]